Cytokinetics
$11.759876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$11.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.32 (+2.80%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours
Why Robinhood?
You can buy or sell Cytokinetics and other stocks, options, ETFs, and crypto commission-free!
About CYTK
Cytokinetics, Inc. operates as a biopharmaceutical company, which focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Read More The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.
Employees
156
Headquarters
South San Francisco, California
Founded
1997
Market Cap
616.50M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
995.82K
High Today
$12.28
Low Today
$10.89
Open Price
$10.99
Volume
586.57K
52 Week High
$16.96
52 Week Low
$7.73
Collections
CYTK Earnings
-$0.56
-$0.37
-$0.19
$0.00
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Expected May 7, After Hours